Day One Biopharmaceuticals stock (US23933J1034): FDA decision on tovorafenib shakes up cancer drug story

Day One Biopharmaceuticals faces a key setback in its pediatric brain cancer program after the FDA declined to approve tovorafenib, sending the biotech stock swinging as investors reassess the late?stage pipeline and cash runway.

Day One Biopharmaceuticals is back in focus after the US Food and Drug Administration (FDA) issued a complete response letter for its lead drug candidate tovorafenib in pediatric brain cancer, forcing the company to rethink its regulatory path and investors to reprice the stock, according to a company press release dated 05/02/2025 and coverage by Reuters as of 05/02/2025.

As of: 19.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Day One Biopharmaceuticals
• Sector/industry: Biotechnology, oncology
• Headquarters/country: South San Francisco, United States
• Core markets: Targeted cancer therapies, pediatric and adult oncology
• Key revenue drivers: Potential future sales of tovorafenib and follow?on pipeline candidates
• Home exchange/listing venue: Nasdaq (ticker: DAWN)
• Trading currency: US dollar (USD)

Day One Biopharmaceuticals: core business model

Day One Biopharmaceuticals focuses on developing targeted cancer drugs that are designed for patients of all ages but with a particular emphasis on children, an area that has historically seen fewer dedicated therapies. The company’s strategy is to in?license or discover precision oncology assets and advance them into late?stage development for genetically defined tumors.

The most advanced program is tovorafenib, an oral, brain?penetrant inhibitor of RAF kinases aimed at tumors driven by alterations in the MAPK pathway. Day One Biopharmaceuticals initially concentrated on pediatric low?grade glioma, a slow?growing brain tumor that can still lead to significant morbidity, and then expanded clinical testing into additional solid tumor indications, according to company filings and clinical updates published on 03/26/2024 by the firm’s investor relations site Day One Biopharmaceuticals IR as of 03/26/2024.

The business model is typical for US development?stage biotech groups: the company currently generates no product revenue and relies on equity offerings and milestone?based collaborations to fund its clinical trials. Operating expenses are driven mainly by research and development spending and the build?out of a small commercial infrastructure in anticipation of possible product launches.

Main revenue and product drivers for Day One Biopharmaceuticals

The primary potential revenue driver for Day One Biopharmaceuticals is tovorafenib, also known by the development code DAY101. In a registrational Phase 2 trial in pediatric low?grade glioma, the therapy showed substantial tumor shrinkage rates, which formed the basis of the company’s initial new drug application submitted to the FDA. These clinical results were detailed in an update published on 06/04/2023, when the company highlighted objective response data that it believed could support an accelerated approval pathway, as described by Day One Biopharmaceuticals IR as of 06/04/2023.

In addition to pediatric low?grade glioma, Day One Biopharmaceuticals has tested or is testing tovorafenib in other solid tumors with aberrant RAF or related signaling, including adult populations. The company’s long?term commercial story, should the drug ultimately secure approvals, would likely depend on expanding into broader tumor types and age groups, thereby increasing the patient pool beyond the relatively small pediatric niche.

Beyond tovorafenib, Day One Biopharmaceuticals maintains a pipeline of earlier?stage candidates targeting similar oncogenic pathways. These follow?on programs are designed to sustain growth after any initial launch and potentially create combination regimens, but they are far from commercialization. For now, investors largely anchor their valuation expectations to the probability and timing of regulatory success for tovorafenib in the United States and, later, in international markets.

Conclusion

Day One Biopharmaceuticals sits at a critical juncture after the FDA’s decision not to approve tovorafenib on its first attempt, a development that underscores both the scientific promise and regulatory uncertainty common in oncology drug development. The company retains a focused pipeline, experience in precision cancer research, and access to US capital markets via its Nasdaq listing, but its future will depend on how effectively it addresses regulators’ concerns, manages cash, and executes any revised clinical and filing strategy for tovorafenib and other assets.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.